Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imNK
- Development stage
- Preclinical
- Lead developer
- Therabest
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
imNK (immuno-modulatory natural killer cells) is a preclinical-stage natural killer (NK) cell therapy being developed by Therabest for the treatment of Alzheimer's disease. The therapeutic approach utilizes activated NK cells to restore the impaired phagocytic and autophagic functions of microglia, which are crucial for clearing amyloid-beta plaques in the brain. In preclinical mouse models of Alzheimer's disease, intravenous administration of imNK cells demonstrated a reduction in amyloid-beta plaque accumulation in the cortex and dentate gyrus of the hippocampus, along with improvements in cognitive decline and neuroinflammation. Therabest is leveraging these preclinical findings to advance an induced pluripotent stem cell (iPSC)-derived 'off-the-shelf' NK cell therapy (EiNK) into clinical development for Alzheimer's disease.
- Other names
- immuno-modulatory NKimmuno-modulatory NK cells면역조절 NK 세포치료제
02
Targets
Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on imNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imNK.